166 related articles for article (PubMed ID: 27128835)
1. Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment.
Halabi A; Maatouk H; Siegler KE; Faisst N; Hinrichsen H
Clin Pharmacol Drug Dev; 2014 Jul; 3(4):290-6. PubMed ID: 27128835
[TBL] [Abstract][Full Text] [Related]
2. Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany.
Nakamaru Y; Hayashi Y; Sekine M; Kinoshita S; Thompson J; Kawaguchi A; Davies M; Jürgen Heuer H; Yamazaki H; Akimoto K
Clin Ther; 2014 May; 36(5):760-9. PubMed ID: 24726088
[TBL] [Abstract][Full Text] [Related]
3. Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling.
Nakamaru Y; Emoto C; Shimizu M; Yamazaki H
Biopharm Drug Dispos; 2015 Apr; 36(3):148-62. PubMed ID: 25450725
[TBL] [Abstract][Full Text] [Related]
4. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans.
Nakamaru Y; Hayashi Y; Ikegawa R; Kinoshita S; Perez Madera B; Gunput D; Kawaguchi A; Davies M; Mair S; Yamazaki H; Kume T; Suzuki M
Xenobiotica; 2014 Mar; 44(3):242-53. PubMed ID: 23855261
[TBL] [Abstract][Full Text] [Related]
5. The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.
Ceriello A; De Nigris V; Iijima H; Matsui T; Gouda M
Drugs; 2019 May; 79(7):733-750. PubMed ID: 30982160
[TBL] [Abstract][Full Text] [Related]
6. Investigation of Potential Pharmacokinetic Interactions Between Teneligliptin and Metformin in Steady-state Conditions in Healthy Adults.
Nakamaru Y; Hayashi Y; Davies M; Jürgen Heuer H; Hisanaga N; Akimoto K
Clin Ther; 2015 Sep; 37(9):2007-18. PubMed ID: 26212570
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers.
Kinoshita S; Kondo K
Expert Opin Drug Metab Toxicol; 2015 Jan; 11(1):7-14. PubMed ID: 25424014
[TBL] [Abstract][Full Text] [Related]
8. Effect of hepatic or renal impairment on eltrombopag pharmacokinetics.
Bauman JW; Vincent CT; Peng B; Wire MB; Williams DD; Park JW
J Clin Pharmacol; 2011 May; 51(5):739-50. PubMed ID: 20663991
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of Teneligliptin in Subjects With Renal Impairment.
Halabi A; Maatouk H; Siegler KE; Faisst N; Lufft V; Klause N
Clin Pharmacol Drug Dev; 2013 Jul; 2(3):246-54. PubMed ID: 27121786
[TBL] [Abstract][Full Text] [Related]
10. Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment.
Hoover R; Marbury TC; Preston RA; Quintas M; Lawrence LE; Paulson SK; Luke DR; Cammarata SK
J Clin Pharmacol; 2017 Mar; 57(3):328-335. PubMed ID: 27570245
[TBL] [Abstract][Full Text] [Related]
11. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin.
He YL; Sabo R; Campestrini J; Wang Y; Ligueros-Saylan M; Lasseter KC; Dilzer SC; Howard D; Dole WP
Eur J Clin Pharmacol; 2007 Jul; 63(7):677-86. PubMed ID: 17486328
[TBL] [Abstract][Full Text] [Related]
12. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.
Kobalava Z; Villevalde S; Kotovskaya Y; Hinrichsen H; Petersen-Sylla M; Zaehringer A; Pang Y; Rajman I; Canadi J; Dahlke M; Lloyd P; Halabi A
Br J Clin Pharmacol; 2015 Jun; 79(6):937-45. PubMed ID: 25511105
[TBL] [Abstract][Full Text] [Related]
14. The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor.
Lawendy N; Lamba M; Chan G; Wang R; Alvey CW; Krishnaswami S
Clin Pharmacol Drug Dev; 2014 Nov; 3(6):421-7. PubMed ID: 27129117
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of linagliptin in subjects with hepatic impairment.
Graefe-Mody U; Rose P; Retlich S; Ring A; Waldhauser L; Cinca R; Woerle HJ
Br J Clin Pharmacol; 2012 Jul; 74(1):75-85. PubMed ID: 22242621
[TBL] [Abstract][Full Text] [Related]
16. An effect of moderate hepatic impairment on the pharmacokinetics and safety of darapladib.
Magee MH; Shearn S; Shaddinger B; Fang Z; Glaser R
Br J Clin Pharmacol; 2014 Nov; 78(5):1014-21. PubMed ID: 24938621
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of teneligliptin in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring.
Yajima T; Yajima K; Hayashi M; Takahashi H; Yasuda K
Diabetes Res Clin Pract; 2016 Dec; 122():78-83. PubMed ID: 27810689
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
Zhao Q; Iyer GR; Verhaeghe T; Truyen L
J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
[TBL] [Abstract][Full Text] [Related]
19. Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: Focus on glycemic control, hypotensive effect, and safety Chikushi Anti-Diabetes Mellitus Trial-Teneligliptin (CHAT-T).
Takamiya Y; Okamura K; Shirai K; Okuda T; Kobayashi K; Urata H
Clin Exp Hypertens; 2020; 42(3):197-204. PubMed ID: 30974980
[No Abstract] [Full Text] [Related]
20. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin.
Boulton DW; Li L; Frevert EU; Tang A; Castaneda L; Vachharajani NN; Kornhauser DM; Patel CG
Clin Pharmacokinet; 2011 Apr; 50(4):253-65. PubMed ID: 21348538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
